Abstract
Background/Aim. Peripheral nervous system affection in people with lung cancer is commonly associated with paraneoplastic neuropathy. However, clinical studies evaluating the frequency, clinical, and electrophysiological characteristics of peripheral neuropathies which are not related to onconeuronal antibodies, in this, on average, older population of patients, are very rare. The aim of this study was to define the frequency, as well as clinical and electrophysiological characteristics of idiopathic neuropathies in patients suffering from lung cancer in early stages of the diseases. Methods. Clinical and electrophysiological data of 105 elderly subjects (age 63.4 ± 7.8 years) suffering from lung carcinoma who underwent extensive neurological and electrophysiological evaluation (nerve conduction studies) between 2013–2018 were estimated. Exclusion criteria were “classical” paraneoplastic neurological syndromes with onconeuronal antibodies present, as well as patients with typical known causes of peripheral neuropathy (e.g. diabetes, alcoholism, chronic renal insufficiency, vitamin deficiencies, etc.). Results. There were 19.1% patients with clinically manifest neuropathies, with additional 37.1% patients with only electrophysiological abnormalities. The most frequent pathophysiological pattern was axonal pathology (71.2%) with predominantly distal and symmetrical distribution (86.4%). Conclusion. Patients with lung cancer in the early stages of the disease show a high incidence of clinically minor damage of the nerves, according to the pattern of chronic sensomotor distal neuropathy, with predominance of axonal damage. These findings underline the importance of a detailed clinical and electrophysiological evaluation in this category of patients who are without the typical etiological factors for peripheral neuropathies since, during cancer therapy, patients undergo a series of treatments with additional risk for the development/aggravation of neuropathy.
Keywords
polyneuropathies
comorbidity
aged
electrophysiology
References
Blum TG, Rich A, Baldwin D, Beckett P, De Ruysscher D, Faivre-Finn C, et al. The European initiative for quality management in lung cancer care. Eur Respir J 2014; 43(5): 1254–77.
Dubey AK, Gupta U, Jain S. Epidemiology of lung cancer and approaches for its prediction: a systematic review and analysis. Chin J Cancer 2016; 35(1): 71.
Kanaji N, Watanabe N, Kita N, Bandoh S, Tadokoro A, Ishii T, et al. Paraneoplastic syndromes associated with lung cancer. World J Clin Oncol 2014; 5(3): 197–223.
Iannuzzi MC, Scoggin CH. Small cell lung cancer. Am Rev Respir Dis 1986; 134(3): 593–608.
Elrington GM, Murray NM, Spiro SG, Newsom-Davis J. Neuro-logical paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. J Neurol Neurosurg Psychiatry 1991; 54(9): 764–7.
Ruelle L, Bentea G, Sideris S, El Koulali M, Holbrechts S, Lafitte JJ, et al. Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature Part 4: Neu-rological paraneoplastic syndromes, involving the peripheral nervous system and the neuromuscular junction and muscles. Lung Cancer 2017; 111: 150–63.
Croft PB, Wilkinson M. The incidence of carcinomatous neu-romyopathy in patients with various types of carcinoma. Brain 1965; 88(3): 427–34.
Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75(8): 1135–40.
Key Statistics for Small Cell Lung Cancer. Atlanta, GA: American Cancer Society, Inc; 2018. Available from: https://www.cancer.org/cancer/small-cell-lung-cancer/about/key-statistics.html [accessed 2018 March 2].
Hanewinckel R, van Oijen M, Ikram MA, van Doorn PA. The epi-demiology and risk factors of chronic polyneuropathy. Eur J Epidemiol 2016; 31(1): 5–20.
Baldereschi M, Inzitari M, Di Carlo A, Farchi G, Scafato E, Inz-itari D. ILSA Working Group. Epidemiology of distal sym-metrical neuropathies in the Italian elderly. Neurology 2007; 68(18): 1460–7.
Vrancken AF, Kalmijn S, Buskens E, Franssen H, Vermeulen M, Wokke JH, et al. Feasibility and cost efficiency of a diagnostic guideline for chronic polyneuropathy: a prospective imple-mentation study. J Neurol Neurosurg Psychiatry 2006; 77(3): 397–401
Dyck PJ, Thomas PK. Polyneuropathy due to nutritional defi-ciency and alcohoism. In: Dyck PJ, Thomas PK, editors. Periph-eral Neuropathy. 3rd ed. Philadelphia, PA: W. B. Saunders; 1993. p. 1310–7.
Kimura J. Principles and variations of nerve conduction studies and assessment of individual nerves. In: Kimura J, editor. Elec-trodiagnosis in diseases of nerve and muscle, principles and practice. 3rd ed. Oxford, UK: Oxford University Press; 2001. p. 91–166.
Cornblath DR, Asbury AK, Albers JW, Feasby TE, Hahn AF, McLeod JG, et al. Research criteria for diagnosis of chronic in-flammatory demyelinating polyneuropathy (CIDP). Neurology 1991; 41(5): 617–8.
Camdessanché JP, Antoine JC, Honnorat J, Vial C, Petiot P, Con-vers P, Michel D. Paraneoplastic peripheral neuropathy associ-ated with anti-Hu antibodies. A clinical and electrophysiologi-cal study of 20 patients. Brain 2002; 125(Pt 1): 166–75.
Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr KM, Peters S. ESMO Guide-lines Working Group. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 Suppl 3: iii27–39.
Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 2003; 123(1 Suppl): 21S–49S.
Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahio-tis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the sur-veillance, epidemiologic, and end results database. J Clin On-col 2006; 24(28): 4539–44.
Antoine JC, Mosnier JF, Absi L, Convers P, Honnorat J, Michel D. Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies. J Neurol Neurosurg Psychiatry 1999; 67(1): 7–14.
Lancaster E. Paraneoplastic Disorders. Continuum (Minneap Minn) 2017; 23(6, Neuro-oncology): 1653–79.
Chia L, Fernandez A, Lacroix C, Adams D, Planté V, Said G. Contribution of nerve biopsy findings to the diagnosis of disa-bling neuropathy in the elderly. A retrospective review of 100 consecutive patients. Brain 1996; 119( Pt 4): 1091–8.
Kararizou E, Karandreas N, Davaki P, Davou R, Vassilopoulos D. Polyneuropathies in teenagers: a clinicopathological study of 45 cases. Neuromuscul Disord 2006; 16(5): 304–7.
Burns TM, Mauermann ML. The evaluation of polyneuropa-thies. Neurology 2011; 76(7 Suppl 2): S6–13.
Notermans NC, Wokke JH, van der Graaf Y, Franssen H, van Dijk GW, Jennekens FG. Chronic idiopathic axonal polyneuropathy: a five year follow up. J Neurol Neurosurg Psychiatry 1994; 57(12): 1525–7.
Visser NA, Notermans NC, Teding van Berkhout F, van den Berg LH, Vrancken AF. Chronic obstructive pulmonary disease is not a risk factor for polyneuropathy: A prospective controlled study. Chron Respir Dis 2017; 14(4): 327–333.
Samuelsson K, Press R. Microangiopathy-A Potential Contrib-uting Factor to Idiopathic Polyneuropathy: A Mini Review. Front Neurol 2018; 9: 43.